Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus…
Recalled by Slate Run Pharmaceuticals
Class III — least serious
Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
Slate Run Pharmaceuticals has recalled Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus…, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on March 4, 2026 and was initiated on February 12, 2026. It is classified as a Class III recall, which means using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus…, with approximately N/A affected. The company behind the recall is Slate Run Pharmaceuticals, based in Columbus, OH. The FDA describes the product as: “Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 57112…”
Why was Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus… recalled?
According to the FDA, the stated reason for the recall is: “Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.”
What should you do?
If you think you may have bought Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus…, compare it against the product description and identifying codes (All lots within expiry) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Slate Run Pharmaceuticals or your local health authority.
About this recall
This recall was distributed in OH. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Full recall details
- Status
- Ongoing
- Date reported
- March 4, 2026
- Recall started
- February 12, 2026
- Distributed in
- OH
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus… recalled?+
According to the FDA: Labeling: Not Elsewhere Classified.
How serious is this recall?+
Class III — least serious. Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
What should I do if I have Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus…?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0343-2026. Information last synced from the FDA on July 6, 2026.